5 news items
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
GMAB
14 May 24
with AbbVie, we are committed to advancing and evolving the robust development program evaluating epcoritamab, as a monotherapy and in combination, across B
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs to extend and improve patients' lives
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GMAB
PFE
29 Apr 24
cancer, genitourinary cancer, hematology-oncology and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
ABBV
GMAB
27 Feb 24
)
sBLA submission demonstrates Genmab's commitment to exploring potential utility of epcoritamab across B-cell malignancies
- Prev
- 1
- Next